To assess the effects of olopatadine of the release of mast cell...
Date First Received: October 13, 2006
Last Updated: September 10, 2007
Verified by: Alcon Research, September 2007
Clinical Trial Phase: Phase 4 | Start Date: October 2006
Overall Status: Completed
Estimated Enrollment: 25
Brief Summary
Official Title: “Mast-Cell Stabilizing Effects of Olopatadine”
Condition Keyword(s):
Intervention(s):
To assess the effects of olopatadine of the release of mast cell histamine
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Pharmacodynamics Study
Intervention(s) in this Clinical Trial
- Drug: Olopatadine (generic name)
Outcome Measures for this Clinical Trial
Primary Measures
- Tear histamine
Secondary Measures
- Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Asymptomatic and not using any topical or systemic medication
Exclusion Criteria:
- Age
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: Alcon Research
Overall Clinical Trial Officials and Contacts
Terry Wiernas Study Director Alcon Research
Additional Information
Information obtained from ClinicalTrials.gov on November 19, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00389025
Study ID Number: C-05-30
ClinicalTrials.gov Identifier: NCT00389025
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
